Your browser doesn't support javascript.
loading
Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling.
van Vliet, Nicolien A; Bos, Maxime M; Thesing, Carisha S; Chaker, Layal; Pietzner, Maik; Houtman, Evelyn; Neville, Matt J; Li-Gao, Ruifang; Trompet, Stella; Mustafa, Rima; Ahmadizar, Fariba; Beekman, Marian; Bot, Mariska; Budde, Kathrin; Christodoulides, Constantinos; Dehghan, Abbas; Delles, Christian; Elliott, Paul; Evangelou, Marina; Gao, He; Ghanbari, Mohsen; van Herwaarden, Antonius E; Ikram, M Arfan; Jaeger, Martin; Jukema, J Wouter; Karaman, Ibrahim; Karpe, Fredrik; Kloppenburg, Margreet; Meessen, Jennifer M T A; Meulenbelt, Ingrid; Milaneschi, Yuri; Mooijaart, Simon P; Mook-Kanamori, Dennis O; Netea, Mihai G; Netea-Maier, Romana T; Peeters, Robin P; Penninx, Brenda W J H; Sattar, Naveed; Slagboom, P Eline; Suchiman, H Eka D; Völzke, Henry; Willems van Dijk, Ko; Noordam, Raymond; van Heemst, Diana.
Afiliação
  • van Vliet NA; Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands.
  • Bos MM; Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands.
  • Thesing CS; Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.
  • Chaker L; Amsterdam UMC, Vrije Universiteit, Department of Psychiatry, Amsterdam Public Health research institute, Amsterdam, The Netherlands.
  • Pietzner M; Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.
  • Houtman E; Academic Center for Thyroid Diseases, Erasmus MC, Rotterdam, The Netherlands.
  • Neville MJ; Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • Li-Gao R; Computational Medicine, Berlin Institute of Health (BIH), Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Trompet S; Department of Biomedical Data Sciences, section of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Mustafa R; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford, UK.
  • Ahmadizar F; Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK.
  • Beekman M; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Bot M; Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands.
  • Budde K; MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Christodoulides C; Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.
  • Dehghan A; Department of Biomedical Data Sciences, section of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Delles C; Amsterdam UMC, Vrije Universiteit, Department of Psychiatry, Amsterdam Public Health research institute, Amsterdam, The Netherlands.
  • Elliott P; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
  • Evangelou M; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford, UK.
  • Gao H; Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK.
  • Ghanbari M; MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • van Herwaarden AE; Dementia Research Institute at Imperial College London, London, UK.
  • Ikram MA; Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Jaeger M; MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Jukema JW; Dementia Research Institute at Imperial College London, London, UK.
  • Karaman I; NIHR Biomedical Research Centre, Imperial College London, London, UK.
  • Karpe F; BHF Imperial College Centre for Research Excellence, Imperial College London, London, UK.
  • Kloppenburg M; Department of Mathematics, Faculty of Natural Sciences, Imperial College London, London, UK.
  • Meessen JMTA; MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Meulenbelt I; Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.
  • Milaneschi Y; Department of Laboratory Medicine, Radboud Laboratory for Diagnostics (RLD), Radboud University Medical Center, Nijmegen, The Netherlands.
  • Mooijaart SP; Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.
  • Mook-Kanamori DO; Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Netea MG; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Netea-Maier RT; Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Peeters RP; Netherlands Heart Institute, Utrecht, The Netherlands.
  • Penninx BWJH; MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Sattar N; Dementia Research Institute at Imperial College London, London, UK.
  • Slagboom PE; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford, UK.
  • Suchiman HED; Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK.
  • Völzke H; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Willems van Dijk K; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Noordam R; Department of Biomedical Data Sciences, section of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
  • van Heemst D; Department of Orthopaedics, Leiden University Medical Center, Leiden, The Netherlands.
BMC Med ; 19(1): 266, 2021 11 03.
Article em En | MEDLINE | ID: mdl-34727949
BACKGROUND: Observational studies suggest interconnections between thyroid status, metabolism, and risk of coronary artery disease (CAD), but causality remains to be proven. The present study aimed to investigate the potential causal relationship between thyroid status and cardiovascular disease and to characterize the metabolomic profile associated with thyroid status. METHODS: Multi-cohort two-sample Mendelian randomization (MR) was performed utilizing genome-wide significant variants as instruments for standardized thyrotropin (TSH) and free thyroxine (fT4) within the reference range. Associations between TSH and fT4 and metabolic profile were investigated in a two-stage manner: associations between TSH and fT4 and the full panel of 161 metabolomic markers were first assessed hypothesis-free, then directional consistency was assessed through Mendelian randomization, another metabolic profile platform, and in individuals with biochemically defined thyroid dysfunction. RESULTS: Circulating TSH was associated with 52/161 metabolomic markers, and fT4 levels were associated with 21/161 metabolomic markers among 9432 euthyroid individuals (median age varied from 23.0 to 75.4 years, 54.5% women). Positive associations between circulating TSH levels and concentrations of very low-density lipoprotein subclasses and components, triglycerides, and triglyceride content of lipoproteins were directionally consistent across the multivariable regression, MR, metabolomic platforms, and for individuals with hypo- and hyperthyroidism. Associations with fT4 levels inversely reflected those observed with TSH. Among 91,810 CAD cases and 656,091 controls of European ancestry, per 1-SD increase of genetically determined TSH concentration risk of CAD increased slightly, but not significantly, with an OR of 1.03 (95% CI 0.99-1.07; p value 0.16), whereas higher genetically determined fT4 levels were not associated with CAD risk (OR 1.00 per SD increase of fT4; 95% CI 0.96-1.04; p value 0.59). CONCLUSIONS: Lower thyroid status leads to an unfavorable lipid profile and a somewhat increased cardiovascular disease risk.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tireotropina / Doenças Cardiovasculares Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tireotropina / Doenças Cardiovasculares Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article